Market Overview

Thoratec Announces Approval for HeartMate II in Japan

Related THOR
Thoratec Announces First HeartMate III™ Human Implant And Start Of CE Mark Trial
Balanced View on Thoratec Corp. - Analyst Blog

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II® ^ as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure.

Posted-In: News


Most Popular

Related Articles (THOR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free